查看文章

The development of effective antiepileptic drugs (AEDs) is crucial in the management of epilepsy, a chronic neurological disorder characterized by recurrent seizures. In order to identify potential AEDs, researchers employ a range of screening models that encompass both in-vitro and in-vivo approaches. These models provide valuable insights into the pharmacological properties and mechanisms of action of candidate compounds, aiding in the selection and optimization of drug candidates for further development. In-vitro screening models involve conducting experiments on isolated cells or tissues in controlled laboratory conditions. They allow researchers to examine the effects of AEDs on specific molecular targets involved in epileptogenesis, such as ion channels or neurotransmitter receptors. In-vitro models offer advantages such as cost-effectiveness, high throughput capacity, and the ability to study drug interactions with isolated components of the nervous system. Furthermore, they facilitate mechanistic investigations that elucidate the underlying pathways through which AEDs exert their antiepileptic effects. Hence, this review was focused for the various methods indicating the In-vitro and In-vivo pharmacological screening models for antiepileptic drugs.